L Oreal extends its RNAi beauty partnership. New OliX agreement broadens focus to nail health

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-29, 17:20.

L Oreal (FR0000125486) on June 29, 2026 was named in a new pipeline partnership agreement with Korean RNA interference specialist OliX covering next-generation beauty solutions. The Paris-listed CAC 40 group continues to trade on Euronext Paris as a major consumer staples stock.

New RNAi deal with OliX

According to a June 29 report from Seoul Economic Daily, OliX signed a fresh pipeline partnership agreement with L Oreal Group to jointly develop RNA interference-based beauty applications targeting hair, nail and skin health in several categories.Seoul Economic Daily coverage of the OliX-L Oreal partnership

The article highlights that the new agreement builds on a prior small interfering RNA research program launched last year by the two companies, which focused on skin and hair regeneration and aging. The latest contract is framed as an extension that widens the collaboration to nail health and begins joint discovery efforts for new candidate substances in beauty science.

Scope and structure of the collaboration

The Seoul Economic Daily report explains that under the new agreement L Oreal will contribute strategic and scientific expertise in beauty science, as well as provide research funding to support joint development activities, while OliX will lead overall research across candidate discovery, R&D and program management.Details on roles of L Oreal and OliX in the RNAi partnership

The publication notes that unlike the previous collaboration, the redesigned agreement is structured to allow multiple research programs to run in parallel, which is intended to accelerate the discovery of RNAi-based cosmetic solutions across hair, nail and skin segments. This multi-program framework underscores L Oreal's interest in scaling biotech-driven innovation in its product pipeline beyond single-point projects.

Analyst consensus on the CAC 40 beauty stock

A June 29 dispatch on ad-hoc-news reports that L Oreal remains a key constituent of the CAC 40 index in Paris and is widely covered by major international brokers, with a broadly supportive stance on the consumer staples stock based on compiled consensus figures.Ad-hoc-news overview of L Oreal analyst consensus

The same article indicates that broker updates in recent weeks show houses such as Goldman Sachs, JPMorgan and UBS maintaining predominantly Buy or Neutral ratings on L Oreal, reflecting its positioning as a defensive growth name among European equities. Compiled data for late June 2026 suggest that a clear majority of analysts rate L Oreal stock Buy or Outperform, while a smaller group sits at Hold and very few at Sell, according to consensus providers tracking recommendations for the Paris-listed shares.Analyst consensus and price target overview for L Oreal

Price levels and market metrics in late June

The ad-hoc-news analyst piece notes that L Oreal shares recently traded around 440 euros on Euronext Paris, implying a market capitalization near 220 billion euros in June 2026 based on exchange data.Exchange-derived price and market cap data for L Oreal

The same source lists L Oreal under the consumer staples - personal care and cosmetics industry classification and confirms its membership in the CAC 40 index, underlining the stock's role as a core holding in many consumer and luxury-focused portfolios. The article mentions a next earnings date of July 31, 2026 for L Oreal, based on calendar information compiled for the group.

What the company sells

L Oreal derives most of its revenue from beauty and personal care products, spanning categories such as skincare, haircare, hair color, makeup and fragrances across mass-market and premium brands. The group markets lines including L Oreal Paris, Maybelline and Garnier, alongside high-end labels under its luxury division.

Where the stock trades today

As of 2026-06-29, 07:10 L Oreal shares were quoted at around 440 euros on Euronext Paris, according to the ad-hoc-news market overview, with that level corresponding to a market capitalization of roughly 220 billion euros for the CAC 40 constituent.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.